WuXi AppTec's Sale of Advanced Therapies Unit Likely to Alleviate U.S. Concerns -- Market Talk

Dow Jones2024-12-27

0252 GMT - WuXi AppTec's sale of its Advanced Therapies unit is likely to alleviate U.S. security concerns, Citi Research analysts write in a note. The cell and gene therapy manufacturing unit is the business segment that the U.S. is worried about and affected by the Biosecure Act, which could restrict WuXi's operations in the U.S., Citi says. The sale will allow transactions to continue without interrupting patient treatments, Citi adds. Given the limited time left for the Senate to vote on the Biosecure Act under the Biden Administration, it lowers the geopolitical risks for WuXi going into 2025, Citi says. Citi retains a buy rating with a target price of HK$74.00. Shares are 3.2% lower at HK$53.85. (kimberley.kao@wsj.com)

(END) Dow Jones Newswires

December 26, 2024 21:52 ET (02:52 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494844859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494844859","market":"fut","top_or_hot":-1,"title":"WuXi AppTec's Sale of Advanced Therapies Unit Likely to Alleviate U.S. Concerns -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0252 GMT - WuXi AppTec's sale of its Advanced Therapies unit is likely to alleviate U.S. security concerns, Citi Research analysts write in a note. The cell and gene therapy manufacturing unit is the business segment that the U.S. is worried about and affected by the Biosecure Act, which could restrict WuXi's operations in the U.S., Citi says. The sale will allow transactions to continue without interrupting patient treatments, Citi adds. Given the limited time left for the Senate to vote on the Biosecure Act under the Biden Administration, it lowers the geopolitical risks for WuXi going into 2025, Citi says. Citi retains a buy rating with a target price of HK$74.00. Shares are 3.2% lower at HK$53.85. (kimberley.kao@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2024 21:52 ET (02:52 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi AppTec's Sale of Advanced Therapies Unit Likely to Alleviate U.S. Concerns -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi AppTec's Sale of Advanced Therapies Unit Likely to Alleviate U.S. Concerns -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-27 10:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0252 GMT - WuXi AppTec's sale of its Advanced Therapies unit is likely to alleviate U.S. security concerns, Citi Research analysts write in a note. The cell and gene therapy manufacturing unit is the ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6088","symbol_name":"石油天然气设备与服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2494844859","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494844859","pubTimestamp":1735267920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0252 GMT - WuXi AppTec's sale of its Advanced Therapies unit is likely to alleviate U.S. security concerns, Citi Research analysts write in a note. The cell and gene therapy manufacturing unit is the business segment that the U.S. is worried about and affected by the Biosecure Act, which could restrict WuXi's operations in the U.S., Citi says. The sale will allow transactions to continue without interrupting patient treatments, Citi adds. Given the limited time left for the Senate to vote on the Biosecure Act under the Biden Administration, it lowers the geopolitical risks for WuXi going into 2025, Citi says. Citi retains a buy rating with a target price of HK$74.00. Shares are 3.2% lower at HK$53.85. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","BK6088":"石油天然气设备与服务","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","LU1997245177.USD":"安联神洲A股基金","BK0216":"研究试验","AEIS":"先进能源工业公司","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BLZ.SI":"爱文思控股","BK4157":"电子设备和仪器","BK6522":"化石燃料股","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD"},"translate_title":"药明康德出售先进疗法部门可能会缓解美国的担忧——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9,"AEIS":1,"BLZ.SI":1},"content_text":"0252 GMT - WuXi AppTec's sale of its Advanced Therapies unit is likely to alleviate U.S. security concerns, Citi Research analysts write in a note. The cell and gene therapy manufacturing unit is the business segment that the U.S. is worried about and affected by the Biosecure Act, which could restrict WuXi's operations in the U.S., Citi says. The sale will allow transactions to continue without interrupting patient treatments, Citi adds. Given the limited time left for the Senate to vote on the Biosecure Act under the Biden Administration, it lowers the geopolitical risks for WuXi going into 2025, Citi says. Citi retains a buy rating with a target price of HK$74.00. Shares are 3.2% lower at HK$53.85. (kimberley.kao@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 26, 2024 21:52 ET (02:52 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494844859"}